LGVN Q3 2024 Earnings — Longeveron Inc. Revenue & Financial Results | Market Cap Arena

LGVNLongeveron Inc.

$20M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$773,000+415.3% YoY

Gross Profit

$682,00088.2% margin

Operating Income

-$5M-601.4% margin

Net Income

-$4M-571.7% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

+65.2%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$30M

Total Liabilities

$4M

Stockholders' Equity

$26M

Cash & Equivalents

$23M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$773,000	$150,000	+415.3%
Gross Profit	$682,000	$54,000	+1163.0%
Operating Income	-$5M	-$5M	+9.9%
Net Income	-$4M	-$5M	+13.5%